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Editorial

ABSTRACT

We have seen four decades of human struggle to cure or eradicate HIV infection since the first clinical detection of HIV infection. Various
developed drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),
protease inhibitors, integrase inhibitors, microbicides, and others have known restrictions, such as side effects and resistance development
when used alone, and hidden reservoir of the virus, which have opened the gates for the involvement of nanomedicine associated systems,
particularly for latent sites of HIV infection. The nanotechnological vehicles, such as liposomes, dendrimers, metal nanoparticles, polymeric
nanocapsules/particles, surfactants, and targeted vehicles have become part of extensive studies for application in real settings for the
delivery of NRTIs, NNRTIs, microbicides, and siRNA. The positional standing of research in quest of potential therapeutics for combating HIV
infection in reference to four decades with this virus need a rational evaluation of nanotechnology to achieve a practical solution to save the
lives.
Keywords: AIDS, Drug Delivery, HIV, Nanobiotechnology, Nanomedicine, siRNA delivery

INTRODUCTION
The patients with an immune system compromised disease,
later designated as Aquired Immune Deficiency Syndrome
(AIDS), were first observed clinically in 1981. Since then, there
have been potential progress in identifying and characterization
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of causative virus, controlling the infection, drug development
and awareness of this infection. These four decades from the first
observation of this infection have witnessed active research in
developing a suitable cure for the virus infection and AIDS.
Though an amicable system to control the infection have been
successful via different drugs and medical technologies still, a
complete cure, particularly for AIDS, is still a subject of major
interest and a goal for medicinal researchers.
The Human Immunodeficiency Virus (HIV), the causative
agent of AIDS and first characterized in 1983, definitively linked
to AIDS in 1984, is a lentivirus known for its delayed onset
leading to this chronic infection. Structurally, it consists of a
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“First identification in 1981 to current
prevalence in 2022 marks the four decades
of known existence of HIV infection”

double-stranded RNA genome with 9,300 base pairs enclosed in
protein capsid. The RNA genome contains three major portions
or open reading frames known as gag (encodes the protein to
form the structural components of the virus), pol (encodes
polyproteins to serve as viral enzymes reverse transcriptase,
integrase, and protease, all of which are required for infecting the
host cells), env (encodes transmembrane proteins for viral
binding on host cell) and six small genes that encode regulatory
proteins.1
The spread of HIV infection is mediated through body fluids
during sex, blood transfusion, and umbilical link. Since the first
identification of this viral infection in New York in 1981, it has
spread to all countries leading to the current known infection of
over 36 million people worldwide; approximately 1.0 million
people die due to AIDS-associated disease with ~ 1.8 million new
infections occurring each year.2
HIV infection starts with the attachment of virus on CD4+ T
lymphocytes, entry of virus into the cells, duplication of the
genome using cellular machinery along with the synthesis of
required proteins, and finally, budding out of new virions. This
causes rupturing of T cells leading to a decline in their numbers;
the continuous repeat of the process ultimately leads to the
immune dysfunction known as AIDS.
Taking this multiplication path of virus in consideration, a
number of different drugs have been approved that target the
different stages of virus multiplication cycle. They include
Fusion inhibitors or entry inhibitors (which target the virus
binding on CCR4 receptors), reverse transcriptase inhibitors (that
target the transcriptase enzyme and include nucleoside reverse
transcriptase inhibitors (NRTIs) (Figure 1) and heterocyclic nonnucleoside reverese transcriptase inhibitors (NNRTIs)), protease
inhibitors (PIs) (inhibits the viral proteins synthesis), fusion
inhibitors (FIs) and integrase inhibitors.3
In general, effective therapy includes the combination of the
above drugs to target multiple stages towards better effective
outcomes. This combination of drugs is known as Highly Active
Anti Retroviral Therapy (HAART) and mostly contains a mixture
of three drugs that may include NRTIs/NNRTIs, Fusion
inhibitors and or Protease inhibitors. The HAART has been
highly successful in controlling the infection and was approved
as standard therapy in 1996.

NRTIs are lead role players in the
management of HIV, constitute an
important part of HAART
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Figure 1. Structure of representative FDA-approved drugs. Structure
of representative first-generation NRTIs approved for HIV treatment
(Apricitabine (ATC) is a recent drug (i.e., a second-generation
NRTI).

The HAART therapy for the treatment of HIV-infected
individuals using a combination of three antiviral drugs approved
by the FDA has been extremely effective in controlling the
infection and further preventing the progression of infection to
AIDS. This has attributed to decline in the AIDS-related deaths
globally. Though HAART can bring the viral load to negligible
(and undetectable) levels, the patients still carry the virus
throughout their lifetime. This arises because of the emerged drug
resistance or due to the presence of the virus in hidden reservoirs
in the individuals’ body where drugs cannot be delivered.4 The
dosage includes frequent administration (once or twice daily) of
antiviral drugs, which leads to other associated toxicities and also
the emergence of drug resistance due to non-compliance of
patients to the required dosage.5
With the current scenario with HIV therapy, the use of medical
nanotechnologies could facilitate achieving higher deliverability,
crossing over of membrane barriers, and generating desired
pharmacological profiles for respective drugs. The meticulous
properties of respective nanosystems have been purposefully
applied with different drugs for different diseases like cancer and
viral infections.6 The prodrug and nanostructured conjugates with
current available HIV drugs have been extensively studied, and
few have reached various stages of clinical evaluations, while
final approved formulations are still treading in the stages of the
clinical trials due to different inherent challenges in preclinical
and clinical requirements of the respective formulation.7
The prodrug and nanotechnological conjugates and derivatives
potentiate the promise of altering the pharmacological profiling
of hydrophilic antiviral drugs along the ability to cross the bloodbrain-barrier to overcome the inability of antiviral drugs to reach
to hidden reservoirs of the virus in parts of the brain and lymph
nodes. Table 1 summarizes some of the prodrug and
nanoformulations that have been approved or are evaluated in
clinical trials. The effective elimination of the virus from these
viral reservoirs requires the sufficient concentration of antiviral
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drugs in the central nervous system and lymphatic nodes.
Furthermore, the introduction of targeted agents in
nanotechnological systems enhances the ability to reach to
specific sites with increased availability of antiviral drugs at
hidden sites of virus and thus can lead to the required effective
elimination of virus from the body.
The prodrug formation of the antiviral drug is the prime step
to improve the bioavailability and cellular uptake of the drugs.
Tenofovir (TFV) 7 and Amprenavir (APV) 10 (Figure 2) are
NRTI and protease inhibitor, respectively, that are administered
in their prodrug forms as the parent drug have limited
bioavailability due to their high hydrophilic or lipophilic nature.
TFV has a phosphonate group which makes it highly hydrophilic
and thus limits its oral administration as the hydrophilic nature of
TFV causes poor membrane permeability leading to negligible
absorption from intestine. The prodrug form of TFV is used to
mask the phosphonate group.8 In tenofovir disoproxil fumarate
(TDF) 8 prodrug, the acyloxyalkyl ester functionalization is used
to mask the negatively charged phosphonate group of TFV, and
thus increases the lipophilicity and oral bioavailability of the
drug. In another prodrug of TFV, tenofovir alafenamide (TAF,
9), the aryl and L-alanine isopropyl ester functionalization of
TFV phosphonate group improves the lipophilicity and
bioavailability. Compared to TDF (8) prodrug, TAF (9) prodrug
was found to be more effective in increasing drug availability at
the site of HIV infection.9

Figure 2. Chemical structures of Tenofovir (TFV), Amprenavir,
and their prodrugs.

Amprenavir (10) has very low water solubity which
compromises its oral bioavailability. It is converted into
fosamprenavir (FPV) prodrug form (11) via the incorporation of
a polar phosphate group. FPV(11) has higher water solubility
compared to amerenavir by virtue of the presence of polar
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phosphate group that is hydrolyzed back to release the more
membrane permeable parent drug amprenavir after oral
administration. All of these three prodrugs: tenofovir disoproxil
fumarate (TDF), tenofovir alafenamide (TAF), and
fosamprenavir (FPV) have been approved by FDA for HIV
treatment.9
In a similar way, NRTIs are also polar due to the presence of
ribose and base structures. Because of their polar nature, the
NRTIs (and also few NNRTIs) have a high rate of biodistribution
and excretion. This higher rate of excretion limits their
bioavailability in the serum as well as at the target site of HIV
infection. The lower bioavailability along with increasing drug
resistance, leads to the administration of high doses of the drug,
which causes the over-burden of dosages on the patient and thus,
generates pronounced associated side effects. Our group has
investigated different methodologies and various prodrug forms
of nucleoside-based and other anticancer drugs to improve their
pharmacological profile.10–19 Similar investigations have been
conducted to circumvent the side effects of NRTIs by
synthesizing different derivatives of parent nucleoside drugs or
by devising various delivery vehicles to reduce the side effects
and increase the availability and potency of the nucleoside-based
drugs.20–23 Alterations in the lipophilicity of NRTIs by the
introduction of a fatty chain with varying degree of lipophilicity
has been a priority option to improve the pharmacological profile
of nucleoside drugs.24 Besides modulation of lipophilicity profile
of NRTIs, the selected fatty acids are also known to inhibit Nmyristoyltransferase (NMT) enzyme, the main enzyme known to
myristoylate various HIV proteins, such as P17 capsid protein,
Pr55gag, Pr160gag-pol, p27nef in the virus-infected cells.25
Myristoylation of proteins allows it to become more hydrophobic
thus enhancing the protein localization at the cellular membrane
and protein-membrane interactions. Certain heteroatomcontaining myristic acid analogs such as 12-thioethyldodecanoic
acid, 4-oxatetradecanoic acid, and 2-methoxydodecanoic acid
exhibited to inhibit the HIV-1 replication in acutely infected Tlymphocytes.26 12-Thioethyldodecanoic acid was found to have
EC50 of 9.4µM and therefore was moderately active against HIVinfected T4 lymphocytes.26 Considering the required modulation
of the lipophilicity profile of NRTIs, the 5′-O-fatty acyl
derivatives of NRTIs were synthesized, which displayed higher
cellular uptake than the parent analogs due to enhanced
lipophilicity and better activity profile.22,23,27,28,29 These ester
conjugates act as bifunctional agents because once it enters the
cells, the esterases hydrolyze the conjugate to release reverse
transcriptase inhibitor (the nucleoside drug) and NMT inhibitor
(the fatty acid). Furthermore, as the lipophilic conjugates are
formed for more than one nucleoside, so it increases potency by
releasing more than one NRTI drugs simultaneously thus helping
to combat the drug resistance.22,23
Similalry some of the synthesized lipophilic derivatives of
lamivudine (3TC, 5) were found to have higher antiviral activity
compared to parent 3TC.29 The 3TC derivatives with
functionalization at NH2 (N4 of pyrimidine base) and 5′-OH (5′O of sugar residue) with varying lengths of alkyl chain were
synthesized (Figure 3). The N4- or 5′-O-monosubstituted
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lipophilic derivatives of the 3TC nucleoside (12-14 and 15-17)
exhibited a higher potency than parent nucleoside 3TC against
cell-free HIV-1. Compared to N4 derivative, compounds with 5’O-monosubstituted ester derivatives (15,16,17) were the most
potent compounds (EC50 = 0.2−2.3 μM) as determined by viral
inhibition single-round infection assays. Among 5′-O-substituted
derivatives, 5′-O-myristoyl analogue (15) exhibited the highest
anti-HIV activity (EC50 = 0.2−0.5 μM). Compound 12 (EC50 =
0.7 μM) was the most potent conjugate against cell-associated
HIV-1 showing approximately 115-fold higher antiviral activity
than 3TC (EC50 = 80.3 μM).29

EC50 = 0.9-1.4μM) exhibited higher anti-HIV activity than AZT
and 3TC against cell-free virus. Compound 20 also displayed
higher anti-HIV activity against multidrug (IC50 = 5.9 nM) and
NNRTI (IC50 = 12.9 nM) resistant viruses than parent
nucleosides. Compound 20 (EC50 = 0.8 μM) exhibited 115-fold
higher activity against cell-associated virus compared to the
physical mixture containing FLT−succinate, AZT, 3TC, and
glutamic acid exhibited (EC50 = 91.9 μM). Similarly, many
additional molecules have been designed with linear and cyclic
peptides for improving the biological activity profile of the
NRTIs and to counter the drug resistance. Most of the these
studies are at laboratory scale with molecules showing varied
properties in vitro assays with possible scope for further
applications and testing for clinical applications.

Figure 3. Chemical structures of lipophilic derivatives of N4 (12,
13, and 14) and 5′-O (15, 16, and 17) substituted 3TC.

In addition to the fatty acids, other moieties such as peptides,
amino acids, etc. have been explored as conjugating units to
deliver more than one NRTI drug simultaneously along with
moiety-mediated21 improved drug delivery.20,22,30 Presence of
more than one nucleoside drug in a single vehicle conjugate
potentiates to circumvent the drug resistance and provide a better
synergistic effect of the released drugs. Prospectively,
combination of lipophilic unit and amino acids on the single
delivery vehicle adds better biocompatibity to the conjugate.20
For example, the glutamic acid conjugates having mono-, di-, and
trinucleoside (NRTIs) conjugates of glutamate or peptide
scaffolds containing nucleoside reverse transcriptase inhibitors
(NRTIs) having fatty acid as part of amino acid scaffold showed
improved activity over multidrug resistance. The selected
derivatives with glutamic acid scaffold are shown in Figure 4.
Among the reported glutamate esters having two nucleosides,
compound 19 (Figure 4), encompassing the conjugated FLT and
FTC, was the most potent anti-HIV agent (EC50 = 0.1-0.4 μM).
Compound 19 displayed superior activity compared to the
individual parent nucleosides FLT and FTC whose activity EC50
values ranges 0.4−2.0 μM. In the dinucleoside glutamate ester
derivatives, N-myristoylated derivatives exhibited significantly
higher anti-HIV activity than the corresponding N-acetylated
conjugates against the cell-free virus.20 Myristoyl-Glu(3TC)-FLT
(18, EC50 = 0.3-0.6 μM) and myristoyl-Glu(FTC)-FLT (19, EC50
= 0.1-0.4 μM) derivatives were the most active glutamatedinucleoside conjugates.30 Among trinucleoside glutamate
derivatives, compound 20 comprising AZT, FLT, and 3TC (20,
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Figure 4. Chemical structures of glutamic acid nucleoside
conjugates. 20 is the triad conjugate having AZT, 3TC, and FLT
attached to glutamic acid succinate. Compounds 18 and 19 are
dinucleoside conjugates of myristoylated glutamic acid.

In addition to anti-HIV drugs that are used systemically, the
microbicides are meant for the local topical delivery or
application of the anti-HIV drug at the site of exposure to prevent
the spread of the virus or acquisition of infection. The
nanoformulations of the anti-HIV agents can potentiate the
prolonged release of the microbicide drugs at the local site for
sustained prevention, enhance the cellular uptake mediated by the
nanosystem deployed, improve the activity of drug due to
encapsulation, and protect the drug from inactivation by the
vaginal microenvironment. With these prepositions, the
microbicides conjugates using gels,31 hydrogels, liposomes,
dendrimers, and polymeric nanoparticles have been developed by
many research groups; however, most of the studies have been
limited to laboratory scale evaluation. The dendrimer named
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VivaGel produced with the naphthalene-3,6-disulfonate
terminated polylysine has been applied to deliver anti-HIV
microbicides in primates. The clinical phase I trial was completed
in 2009 (Table 1),32 however, further developments remained
elusive due to other necessary requirements.33 Similarly,
maraviroc, an anti-HIV drug that binds to human chemokine
receptor CCR5, incorporated in a silicone elastomer gel produced
enhanced and sustained concentrations of this microbicide in the
vaginal tissue in preliminary investigations.34 The microbicides
have offered a better perspective for local application of drugs;
however, formulation development requires more focused
advances oriented towards requirements of local delivery or
microenvironment system at a localized site.
The nanocarrier-based strategies have the potential for
successful application in this regimen. Nanobased formulations
have accoladed their might in the development of therapeutics for
different disease,35 particularly cancer.36,37 The potential
nanocarriers for HIV management encompass polymeric
nanoparticles, solid lipid nanoparticles, liposomes, dendrimers,
biomacromolecules, and metal nanoparticles.38 The polymeric
nanoparticles of poly(lactide-co-glycolide) (PLGA), poly (Llactic acid) (PLA), poly(capro-lactone)
(PL), and
biomacromolecule chitosan nanoparticles have been studied with
different antiviral drugs, Lamivudine,39 Zidovudine,40
Indinavir,41 and Tenofovir.42 Nanogel carriers consisting of PEGor Pluronic-PEI biodegradable networks, star PEG-PEI, or
PAMAM-PEI-PEG dendritic network have shown efficient
delivery of NRTIs, AZT-triphosphate and ddI-triphosphate in
macrophages.43 These nano-Gels on further decoration with
vector peptides (e.g. brain-targeting ApoE peptide) displayed
high delivery in the brain with the highest antiviral efficacy.44
However, most of the above formulations showed a varied degree
of uptake in different cells and most of the studies have been
restricted to a laboratory scale.
Dendrimers are the hyperbranched structures that generate
different types of natural and synthetic materials. They can entrap
the drugs in its structure, cross the blood brain barrier, and have
enhanced cellular uptake profile. The dendrimers have the ability
to be used with antiviral drugs for enhanced cellular uptake and
sustained release of encapsulated drugs. The mannose terminated
dendrimer encapsulated with anti-HIV drug efavirenz showed
sustained release up to 144 hours.45 The stand-alone
poly(amidoamine) (PAMAM) dendrimer and carbosilane
dendrimer has the affinity to bind to cell receptors (gp120 and
CD4), and thus dendrimer itself has anti-HIV effect by
preventing the binding of the virus to cells, indicating the
possibility of use as a microbicide in cervicovaginal tract
applications.46
Lipid nanoparticles such as solid-lipid nanoparticles (SLNs),
liposomes, ethosomes, niosomes, lipid nanoemulsions etc. are
among the leading class of nanoparticles for application in drug
delivery-related studies. Many formulations based on this class
of nanoparticles are in clinical applications, particularly for
anticancer therapies. The SLNs prepared from synthetic lipids in
thin-film hydration exihibit good colloidal stability and can
deliver drugs efficiently.47 Assorted antiviral drugs such as
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Liposomes and lipid-based carrier carry high
potential of applicability and development
of therapeutics for HIV infection

Atazanavir (protease inhibitor (PI)),48 Ritonavir (protease
inhibitor),49 Darunavir (protease inhibitor),50 and nelfinavir.51
encapsulated in SLNs have been observed to enhance the cellular
uptake with higher anti-HIV effect on encapsulation of drug. The
SLN loaded with anti-retroviral drug atazanavir sulfate showed
superior oral bioavailability compared to the free drug. SLNs
exhibited the lymphatic route for transportation of formulation
and have better retention in the site of viral reservoirs, thus
suggesting better applicability of SLNs with antiviral drugs.52
Liposomes are lipid nanostructures with ball-like lipid layer
structure (similar to phospholipid bilayer of cell membrane
structure), excellent cellular uptake properties, easy synthesis,
easy surface modification with targeting/carrier molecules, and
ability to enclose the drug to keep the drug protected during
transportation.53,54 Their robust drug delivery applicability is
accoladed by the presence of different drug-liposome
formulations in the market (Doxil, Depocyt, Visudyne, DipoDur,
DaunoXome, Ambisome etc.).55 The liposomes have also been
studied with different anti-HIV drugs. The liposome-based
carrier system has high potential to deliver the drugs to
macrophages (one of HIV-infected cells) because the
macrophages consider liposomes as foreign particles and engulfs
them. This is one way of directing the delivery of drugs to target
sites.56 Different anti-HIV drugs azidothymidine (zidovudine,
AZT), stavudine (2, 3-didehydro-2,3-dideoxythymidine, d4T),
and indinavir have been evaluated with encapsulation into
surface-modified liposome for targeted delivery of the drugs.57
The
indinavir
encapsulated
in
the
dipalmitoyl
phosphatidylcholine (DPPC) bilayer immunoliposomes showed
much higher uptake in different tissues than in naked drugs
only.57 The storage and biological stability of liposomes can be
enhanced by using the poly(ethylene glycol) (PEG) on liposome
surface or with chitosan or hydroxyapatite coating that will
provide better applicability of liposomes.58 The PEGylated
liposomes loaded with anti-HIV saquinavir drug showed better
colloidal stability and enhanced cellular uptake of the drugliposome formulation compared to the free drug.59 The etravirine
drug loaded on the lipidic nanocarrier showed better uptake and
accumulation in different body organs, such as lymph nodes,
liver, ovary, and brain, compared to the free drug. This selected
enhanced uptake in organs would be beneficial in the eradication
of HIV infection from respective organs.60 The lipid nanocarriers
loaded with the HIV-fusion inhibitor peptide E1P47 were applied
as vaginal microbicide since the formulation has sustained
release of fusion inhibitor peptide;61 its sustained release profile
was much better from lipid formulation compared to similar
release from synthetic PLGA polymer. The vaginal tissue have
better retention of liposomal vesicals.61 Based on these laboratory
scale studies, the liposomes-based anti-HIV drug formulations
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have shown superior potential towards the development of
clinical applicable nanodrug formulation, however, efforts with
thorough and concise evaluation are needed in future studies.
Other lipid nanoparticles like lipid nanosuspensions, niosomes
(self-assembled vesicular structures of non-ionic surfactants),
and ethiosomes (ethanolic liposomes with polyols chains) have
been studied with different anti-HIV drugs for better cellular
uptake; however, varied reasons limited their evaluation only at
experimental level.62
The long-acting nanoformulations are constructed by
converting the drugs in protected structures, such as solid drug
nanoparticles, drug nanocrystals, and sometimes prodrugs. The
long-acting nanoformulation of anti-HIV drugs rilpivirine, a
NNRTI, and cabotegravir, an HIV integrase inhibitor, was
approved by Health Canada under brand name Cabenuva™ for
use once in a month administration by intramuscular route.63
After completing the clinical trials, the drug formulation
Cabenuva
has
been
approved
by
the
FDA.
Cabotegravir/Rilpivirine is, therefore a recent FDA-approved
combinational injectable drug to treat HIV composed of longacting formulation of cabotegravir (second-generation integrase
strand transfer inhibitor) and rilpivirine (NNRTI) (Figure 5).64
The outcomes of clinical trials (ATLAS-2M) study indicated a
good efficacy as well as the safety profile of Cabenuva™
regimen for injection every 8 weeks, offering hope for the
reduced dosing for the management of HIV infection. Thus, the
success of this long-acting formulation can potentiate future
research with other drug combinations.64

Figure 5. Chemical strucutres of Cabotegravir and Rilpivirine,
the drug components of long-acting formulation Cabenuva™.
The nanosuspensions of the NNRTI efavirenz and the protease
inhibitor lopinavir are currently in Phase I clinical trials.65 A
porous solid drug particle, surrounded by a matrix of stabilizers,
is obtained by freeze-drying the frozen emulsion of drugs. The
obtained nanocrystals have high drug loading (70%) and are
suitable for sustained release of drugs.66
Metal nanoparticles constitute the widest variety of nanosized
particles accessible from different metals and metal salts (oxides,
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sulfides), which find applications in diverse fields including
nanobiotechnology, nanocatalysis,67 materials sciences,68,69
among others. The nanoparticles of silver and gold are leading
metal nanoparticles for explorations in different fields due to
their easy synthesis by well-established methods, tunability of
properties, and easy surface functionalization with organic
compounds to alter their surface properties and biocompatibility.
The inherent properties of silver nanoparticles as antibacterials
led to their extensive explorations for applications in various
infectious diseases70 and their functionalization with natural and
synthetic products to enhance the effect.71 The silver
nanoparticles have also been investigated for anti-HIV effect.
The silver nanoparticles synthesized deploying natural plant
extractives have demonstrated the inhibitory effect on reverse
transcriptase and protease enzymes.72,73 In an in vitro vaginal
topical study, the poly(vinylpyrrolidone) (PVP) coated silver
nanoparticles have shown the HIV transmission inhibition.74
The surface plasmon exhibited by gold nanoparticles assists in
the tracking of nanoparticles and detection of nanoparticle-drug
conjugate. Because of the easy surface functionalization of gold
nanoparticles with drugs, biocompatible and/or targeting
molecules makes these nanoparticles suitable for drug delivery
applications. The delivery of anti-HIV drugs using gold
nanoparticles with or without surface modifications has been
explored extensively. The gold nanoparticles coated with glucose
and conjugated with anti-HIV drugs lamivudine and abacavir
through thiol linkage exhibited well-tuned pH dependent release
of drugs.75 The gold nanoparticles coated with mannoglycosaccharides have shown the ability to bind with the lectins
present on the surface of macrophages and thus inhibit the HIV
infection by preventing the dendrite-mediated binding of the
virus to the macrophage cell surface.76 The gold nanoparticles
coated with cyclic and linear peptides have been demonstrated
for enhanced cellular delivery of anti-HIV drugs lamivudine
(3TC) and emtricitabine (FTC) (Figure 1).77 The cyclic peptide
c[KW]5 coated gold nanoparticles showed localization in the
nucleus while linear peptide l(KW)5-AuNPs delivered the
lamivudine drug in the cytoplasm.77 Inclusion of cell-penetrating
cyclic peptide further potentiates the drug delivery using gold
nanoparticles.78
Metal-organic frameworks (MOFs) are emerging as promising
drug delivery vehicles due to their higher amount of drug loading
capacity, biocompatibility, and biodegradability.79 The anti-HIV
drug azidothymidine triphosphate (AZT-TP) loaded up to 24%
onto the nanoMOFs made up of iron trimesate.80 The AZT-TP
loaded nanoMOFs efficiently penetrated and released the drug
inside HIV-infected cells comparatively at a very high
concentration compared to free drug.80 The magnetic
nanoparticles help in controlled release of the drug in response to
external stimuli of the applied magnetic field.81 These
nanoparticles also can be tracked under magnetic resonance
imaging. Many superparamagnetic iron nanoparticle and other
paramagnetic metals serve as drug delivery vehicles for cargo
molecules. In a recent study, the magentic nanoparticles having
dendrion with carboxylate surface functionalization have been
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evaluated for entrapping of HIV-1 strains towards easy and rapid
diagnosis of virus.82
The NRTIs are
important drugs in the therapeutics
development for HIV treatment; however, the development of
long-acting formulations of NRTIs is still lacking; none has
reached clinical trials yet. The NRTIs have hydrophilic
structures, and there is variations of chemical properties of
nanosuspensions of NRTIs in the varied biological
microenvironment. Thus, there is still a need to explore other
delivery nanosystems that can suitably incorporate and release
the drugs. We have used cell-penetrating peptides (CPPs) to
encapsulate and enhance the delivery of a number of NRTIs, such
as 3TC, FTC, and d4T, in different cell lines.83–87 More studies
are required to determine whether the encapsulation and
improved delivery can be translated to long acting effect or
enhanced anti-HIV activity.
Table 1. List of successful nanoconjugates for HIV (clinical stages/
approved).
Nanosystem
Drug used
Formulation
Stage
Prodrug
Tenofovir
tenofovir
In clinics
disoproxil
– FDA
fumarate
approved
Prodrug
Tenofovir
tenofovir
In clinics
alafenamide
– FDA
approved
Prodrug
Amprenavir
fosamprenavir
In clinics
– FDA
approved
Gel
Microbicides
VivaGel
Phase I
trials
NanoCrystals
Cabotegravir
Cabenuva™
Approved
+ rilpivirine
by FDA
and
Health
Canada
Nanocrystals
Efavirenz and Solid
Phase I
lopinavir
nanoparticles of
drugs

The small interfering RNAs (siRNAs) hold the capacity to
inhibit the viral replication in the host cells as these are small
fragments of noncoding RNA that mediate the genetic material
replication inhibition or stop the central dogma to inhibit the
protein synthesis. This phenomenon, known as gene silencing
using siRNA, have high specificity and is advantageous in
targeting siRNA for treating any disease that requires genetic
regulation. The initial analysis of genetic material and subsequent
designing of specific sequence of RNA for targeted action have
potential in therapy of different disease like cancer, diabetes,
brain disease and viral diseases etc. The siRNAs have also been
evaluated for the development of HIV therapeutics. The major
problem with the siRNA is their delivery to target site due to
highly polar nature of the RNA fragments (phosphate backbone).
A number of different vehicles such as lentiviral vehicles and
non-viral nanomaterials such as liposomes, lipids nanoparticles,
carbon nanotubes,88,89 metal nanoparticles and other carriers have
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been studied for the delivery of siRNA. The viral vehicles has
associated immune response which hinder their clinical
application while non-viral nanomaterials vehicles has loading
and continuous release related issues, however, the continuous
efforts have led to the successful clinical applications as evident
by marketed formulations such as (1) Patisiran is the lipid
nanoparticles formulation of the first RNAi based drug approved
in 2018 for treatment of hereditary transthyretin mediated
amyloidosis (hTTR),90 which acts by inhibition of translation of
protein from TTR mRNA; (2) Givosiran is the siRNA conjugated
to Alnylam’s Enhanced stabilization Chemistry Nacetylgalactosamine (ESC-GalNAc) residue meant for the
treatment of acute hepatic porphyria;91 (3) Lumasiran is siRNA
conjugated to ESC-GalNAc for treatment of Hyperoxalurea type
1;92 (4) Inclisiran is the recent siRNA drug conjugated to
GalNAc for the treatment of atherosclerotic cardiovascular
disease.93
In case of siRNA for HIV, different delivery vehicles may be
required to target the different organs as the virus remain located
in different organs including its hidden reservoirs. The siRNA
designing is further complicated by the different strains of the
virus (present in different countries) along with generated
mutations during the lifecycle or propagation of virus from host
to host. The siRNA design as well as delivery vehicle selection
makes it a challenging task for application in HIV therapy.94
The ’block and lock’ strategy is meant to inactivate the virus
by inhibiting the essential parts/proteins involved in transcription
cycle. By targeting the key transcriptional steps, this strategy
might provide a functional cure by keeping the virus in
permanently latent stage.95 Currently, the most studied
therapeutic of “block and lock” is a Tat-inhibitor, didehydrocortistatin A (dCA).96 As the Tat protein is essential unit to
support the RNA polymerase II and its inhibition with dCA have
shown promising results with significant inhibition of virus
replication.97 Another class of inhibitors include the small
molecules based Integrins (LEDGINs) that inhibit integrase
required for the integration of chromatins at active transcription
sites and have given promising results.98 Here, the siRNA comes
in prominent role due to their higher specificity and ability to
target different stages of transcription components.99 This is
transcriptional gene silencing (TGS) where siRNA inhibit the
generation of new virions via inhibition of transcription. The
siRNA can be designed to target the viral RNA or host mRNA
that are necessary for viral replication.100 Though, this
transcriptional gene silencing (TGS) using siRNA promises
efficient output in ‘block and lock’ inhibition, its delivery at
target site remains a challenge for efficient application as the
siRNA are rapidly cleared from circulation as well as not easily
taken up by cells.101 Besides lentiviruses, all other synthetic
nanocarriers such as liposomes, polymer nanoparticles,
nanocapsules, siRNA-polymer conjugates, gold nanoparticles,
glycogen nanocarrier and magnetic nanocarriers have extensively
been studied for delivery of siRNA for HIV therapy.94 Among all
these, the liposomes are presumed and have been most potent
carriers for siRNA delivery as a number of formulations
containing siRNA with liposomes or lipid nanoparticles are
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clinical stages of evaluation for different diseases.90,94 The
liposomes and other carrier subjected for anti-HIV activity with
siRNA have remained in infancy. Thorough evaluation and
development of delivery vehicles with siRNA with consistent
effort in future would bring the desired therapeutics for HIV.

FUTURE PERSPECTIVE
There are currently potent anti-HIV drugs targeting different
events in the life cycle of viruses, such as fusion, reverse
transcription, integration, and protein synthesis. Many of these
drugs are currently used in different combination cocktails, such
as HIV integrase strand transfer inhibitor (INSTI) (e.g.
dolutegravir, bictegravir) or NNRTI (e.g. rilpivirine, etravirine,
doravirine,) plus two or more NRTIs (e.g. tenofovir, lamivudine,
emtricitabine,). and have been able to control the HIV infection
in patients and have transformed the HIV infection as a lethal
disease into a more manageable chronic one. There is still a
problem associated with the adherence to daily oral drug use and
the prevention of drug-resistant viral strains. Furthermore, there
are issues related to drug-drug interactions that may occur
because many patients take other medications. Thus, there is a lot
of interest in developing long-acting formulations. The success
of FDA-approved long-acting cabotegravir and rilpivirine has
revolutionized the field since patients need to have only six
intramuscular injections per year instead of 365 daily pill.
Another recent success story is the development of long-acting
islatravir, an NRTI with a dosing interval of one year or more. It
is envisioned that by using prodrug approaches and different
nanoformulation strategies, several more long-acting
antiretroviral will become available. There is a potential for
implant and patch formulation that would exempt patients from
oral administration and provide a long-term effect. Many implant
formulations need the use of polymers. The therapeutic plasma
level of drug needs to be maintained to avoid viral replication
rebound. Furthermore, long-acting cabotegravir/rilpivirine is an
injectable formulation and needs to be kept at 2-8 °C. Therfore
future formultion should avoid painful modes of administration.
For the implants, there is a need for surgical procedures to
remove and replace implants. Thus, there is still need to develop
more optimized formulations to maximize the therapeutic and
prophylactic potential of long-acting agents. Prodrug and
nanoformulation strategies have the potential to circumvent some
of these problems.

CONCLUSION
The specific chemical and pharmacological profile of antiHIV drugs, such as NRTIs, NNRTIs, PIs, and FIs play a critical
role in their bioavailability in blood serum and at the targeted site
of infection. Though HAART has been quite successful in
eradicating of HIV infection, the drugs used in this combination
therapy, however, could not eliminate the virus completely from
the body. Their low bioavailability and increased drug resistance
potentially require the use of alternate systems, including
nanomedicine for a better outcome. Modulation of these drugs
profile with nanostructured systems and concepts, although
extensively explored, have seen limited success in clinical

Applied Nanomedicine

applications. The prodrugs of selected antiviral drugs are in
clinical use, but the rest of the nanostructured systems are either
in clinical trial stages or require more robust investigations to
make them applicable in clinics for anti-HIV therapy.
Nanomedicine comprising medical nanostructures and
nanoformulations have the potential to reach to the hidden
reservoirs of the virus or circumvent the challenges to cross
membrane barriers (like blood-brain-barrier), and considering
this capability, various systems such as liposomes, solid lipid
nanoparticles, metal nanoparticles, dendrimers, gels, micelles,
and other nanomaterials have been evaluated for possible
development as an applicable vehicle for anti-HIV therapy. With
these efforts, few conjugates or nanosystems have reached to the
clinical trial stages, while others warrant more detailed
evaluation. The nanoconjugate systems have the potential to be
successful in clinical trials, and applicable nanosystems may
reach to clinics in near future, however, research efforts in this
field must focus on the efficient deliverable drug-nanosystem
conjugate having acceptable biocompatibility and appropriate
treatment outcome.
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